ArticleFrontiers in microbiology2025
Low rate of infectious mortality omitting fluoroquinolone prophylaxis in high-risk hematological patients, a single centre experience.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics and risk factor analysis of multidrug-resistant bacterial bloodstream infections in adult acute leukemia patients.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In hematological patients treated with intensive chemotherapy (CHT), febrile neutropenia (FN) is the primary cause of non-relapse mortality (NRM) due to infections that occur during prolonged neutropenia. Fluoroquinolone (FQ) prophylaxis is still recommended by several guidelines for neutropenic patients because it helps reduce bacterial infection rates and fever episodes, although it does not affect infection-related mortality (IRM). However, in the era of multi-drug resistance (MDR), the use of FQs should be evaluated carefully. Methods: We present a retrospective, single-center study based on real-life data that includes 512 intensive chemotherapy treatments and the occurrence of prolonged neutropenia in 236 high-risk (HR) hematological patients treated without FQ prophylaxis. Results: In the entire cohort, we recorded FN in 80.5% of the cases. Among these, 33.7% were attributed to fevers of unknown origin, 45.4% were associated with bloodstream infections (BSIs), 9.0% involved bacterial organ infections, 13.6% were due to fungal infections, and 3.4% were linked to viral infections. Septic shock was observed in 7.6% of the patients. Although we documented a high infection rate, the IRM and overall mortality rates were 3.0% (7/236) and 9.3% (22/236), respectively. These rates are comparable to those found in settings where FQ prophylaxis is used. Conclusion: Although our cohort was small, our results advocate for the exclusion of FQ prophylaxis in HR hematological patients, without increasing the IRM rate and addressing the risk of life-threatening MDR infections. While we believe it is mandatory to have an efficient protocol for the prompt treatment of FN, our data should encourage hematologists to limit the use of FQ prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.